Clinical Trial Update: Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating circulating tumor DNA–guided adaptive therapy using BRAF and MEK inhibitors for melanoma; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: The Christie NHS Foundation Trust | Conditions: Melanoma | Phase 2 | Status: NOT_YET_RECRUITING